Primecap Management Co. CA Trims Holdings in Mural Oncology plc (NASDAQ:MURA)

Primecap Management Co. CA reduced its holdings in shares of Mural Oncology plc (NASDAQ:MURA) by 40.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,045 shares of the company’s stock after selling 95,506 shares during the period. Primecap Management Co. CA owned 0.82% of Mural Oncology worth $438,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of MURA. BBR Partners LLC purchased a new position in shares of Mural Oncology during the second quarter valued at approximately $31,000. Rhumbline Advisers purchased a new position in Mural Oncology during the second quarter valued at $34,000. Commerce Bank bought a new stake in Mural Oncology in the third quarter worth $39,000. Canada Pension Plan Investment Board purchased a new stake in shares of Mural Oncology in the second quarter worth $70,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Mural Oncology during the second quarter valued at $71,000. Institutional investors own 80.21% of the company’s stock.

Insider Activity

In other news, CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total transaction of $25,305.61. Following the transaction, the chief financial officer now directly owns 71,438 shares of the company’s stock, valued at $243,603.58. This represents a 9.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Mural Oncology Stock Performance

NASDAQ MURA opened at $3.35 on Friday. Mural Oncology plc has a one year low of $2.88 and a one year high of $6.25. The stock has a 50-day moving average of $3.41 and a 200 day moving average of $3.37. The company has a market capitalization of $57.02 million and a price-to-earnings ratio of -0.36.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a research report on Monday, November 11th. Raymond James initiated coverage on shares of Mural Oncology in a report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price target on the stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.